ArticleHead & neck2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.
Article in Head & neck, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 110 citations in OpenAlex.
- Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol.Advances in radiation oncology · 2026Trial
- Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial.The Lancet. Haematology · 2024Trial
- Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study.Cancer medicine · 2022Trial
- Salvage ultra-low-dose radiotherapy for conjunctival mantle cell lymphoma - a case report and literature review.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
- Clinical Outcomes and Safety of Ultra-Low-Dose Radiotherapy for Ocular Adnexal Lymphoma: A Systematic Review.Cancers · 2025Review
- Immune Checkpoint Inhibitors in the Treatment of Ocular Surface Cancers: A Review.Seminars in ophthalmology · 2025Review
- The clinical outcomes of ultra-low-dose radiotherapy for primary conjunctival mucosa-associated lymphoid tissue lymphoma.International ophthalmology · 2025Article
- Incidence, clinical features, and survival outcomes of primary malignant conjunctival tumor: a US population-based retrospective cohort analysis based on the SEER database (1975-2018).Translational cancer research · 2025Article
- Subepithelial Lesions of the Ocular Surface: A Review.Current ophthalmology reports · 2025Review
- Fine-Needle Aspiration Biopsy as a Diagnostic Modality for Orbital Adnexal Lymphoma.Acta cytologica · 2024Article
- Radiotherapy of Orbital and Ocular Adnexa Lymphoma: Literature Review and University of Catania Experience.Cancers · 2023Review
- Conjunctival Lymphoma.Eye (London, England) · 2023Review
- Management of Marginal Zone Lymphoma: A Canadian Perspective.Current oncology (Toronto, Ont.) · 2023Review
- Radiation therapy for primary orbital and ocular adnexal lymphoma.Clinical and translational radiation oncology · 2023Article
- Ultra-low-dose radiotherapy in the treatment of ocular adnexal lymphoma: a prospective study.Radiation oncology (London, England) · 2022Article
- Review
- [Treatment and prognosis of primary ocular adnexal extranodal marginal zone mucosa-associated lymphoid tissue lymphoma: a report from a single center].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Ultra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report.Journal of ophthalmic inflammation and infection · 2022Article
- Current Status of the Spectrum and Therapeutics ofCancers · 2022Review
- Review
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
21 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe purpose of this study was to report the response to and toxicity of ultra-low-dose radiotherapy (RT) for B-cell ocular adnexal lymphoma (OAL).
methodsWe conducted a retrospective review of patients with indolent B-cell and mantle cell OAL treated with 4 Gy to the orbit(s) in two 2-Gy fractions. Disease response was assessed clinically and/or radiographically at 2 to 4-month intervals after RT. Data collected included rates of overall response, complete response (CR), partial response (PR), and treatment-related toxic effects.
resultsTwenty-two patients (median age, 65 years) had the following histologic subtypes: mucosa-associated lymphoid tissue (MALT; 14 patients; 64%); follicular lymphoma (5 patients; 23%); mantle cell lymphoma (MCL; 2 patients; 9%); and unclassifiable (1 patient, 4%). The overall response rate was 100%; 19 patients (86%) had a CR and 3 patients (14%) had a PR. The only acute toxic effect was grade 1 dry eye syndrome in 1 patient.
conclusionUltra-low-dose RT in patients with OAL is associated with high response rates and minimal toxic effects, and is much shorter in duration and cost. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1095-1100, 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.